Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03034395 | Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma | completed | N/A | 15 | University of Kansas Medical CenterOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03328247 | Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma(ASICA) | completed | N/A | 240 | University of AberdeenOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT00118274 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 170 | Craig L Slingluff, JrOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT03512457 | Skin Self-Examination Education During Mammography(SSE) | completed | N/A | 420 | Northwestern UniversityOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00896480 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma | completed | Phase 2 | 24 | GlaxoSmithKlineINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT03112668 | Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners | completed | N/A | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT00344799 | Cytogenetic Study of Ocular Melanoma | completed | — | 95 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT01302496 | Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma(TriMix-Ipi) | completed | Phase 2 | 39 | Bart NeynsOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT02110355 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | completed | Phase 1 | 31 | Kartos Therapeutics, Inc.INDUSTRY | 2 | Mar 26, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02085070 | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | completed | Phase 2 | 65 | Yale UniversityOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT00303251 | Safety of TKI258 in Advanced/Metastatic Melanoma Subjects | completed | Phase 1 / Phase 2 | 47 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 11, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02854657 | Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners(PSW) | completed | N/A | 682 | Northwestern UniversityOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04789421 | Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management(NET-DAM) | completed | N/A | 3,248 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 0 | Mar 9, 2021 | clinicaltrials |
| NCT00258687 | Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT00398450 | Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 12 | University of California, San DiegoOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | completed | Phase 1 | 34 | BioNTech US Inc.INDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma(COMBI-v) | completed | Phase 3 | 704 | Novartis PharmaceuticalsINDUSTRY | 28 | Feb 24, 2021 | clinicaltrials |
| NCT02339324 | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | completed | Phase 1 | 31 | Yana NajjarOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT03329755 | Optimization of the Patient Care Pathway in Immuno-oncology(OPTIMMUNO) | completed | N/A | 142 | Institut Claudius RegaudOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT01584648 | A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma | completed | Phase 3 | 423 | Novartis PharmaceuticalsINDUSTRY | 14 | Feb 17, 2021 | clinicaltrials |
| NCT02902042 | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(IMMU-TARGET) | completed | Phase 1 / Phase 2 | 16 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT03163433 | Feedback in the Consultation - a Dialogue-based Tool in Personalised Care Planning Using Systematic Patient Involvement | completed | N/A | 282 | University of AarhusOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT01321437 | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | completed | Phase 2 | 11 | University of California, IrvineOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT02493361 | Trial of pIL-12/MK-3475 in Metastatic Melanoma | completed | Phase 2 | 24 | University of California, San FranciscoOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT00304525 | A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma(CHIR-265-MEL01) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01430416 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | completed | Phase 1 | 153 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02423863 | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®(Poly-ICLC) | completed | Phase 2 | 26 | Oncovir, Inc.INDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT02905266 | A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | completed | Phase 3 | 106 | Bristol-Myers SquibbINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT03326973 | Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors | completed | — | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00942162 | A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma(PREDICT) | completed | Phase 2 | 125 | GlaxoSmithKlineINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT03352947 | Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma(INTERIM) | completed | Phase 2 | 79 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04507048 | Passive Versus Active Educational Interventions for Melanoma Recognition(PAMela) | completed | N/A | 560 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Dec 2, 2020 | clinicaltrials |
| NCT04648163 | Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma | completed | — | 118 | Medical University of GrazOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT01726738 | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | completed | Phase 2 | 17 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 6 | Nov 20, 2020 | clinicaltrials |
| NCT03109327 | Investigating the Clinical Utility of the MDS(OMS002_UK) | completed | — | 250 | Orlucent, IncINDUSTRY | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02177110 | A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma(SYS-ACT) | completed | — | 16 | Cancer Trials IrelandNETWORK | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02159443 | Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody | completed | — | 76 | St. Jude Children's Research HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00901966 | Sun Exposure and Melanoma in Agricultural Workers | completed | — | 447 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2020 | clinicaltrials |
| NCT00471887 | Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma | completed | Phase 2 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT01328535 | Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 25 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03898687 | The Use of Magtrace®/Sentimag® in Sentinel Node Biopsy for Malignant Melanoma. The Magmen Study.(MAGMEN) | completed | N/A | 15 | Sahlgrenska University HospitalOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT04577742 | Uveal Melanoma and Brachytheraphy: Long-term Outcomes. | completed | — | 350 | Federico II UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02771340 | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | completed | Phase 1 | 10 | Iconic Therapeutics, Inc.INDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT00525031 | Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients | completed | Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT00510302 | Melanoma Risk-Reduction Among Patients and Family Members | completed | — | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2020 | clinicaltrials |
Data updated 24 days agoSource updated May 3, 2021source: clinicaltrials